雷贝拉唑治疗小儿幽门螺杆菌十二指肠溃疡疗效观察

Observation on rabeprazole in treating children with H. pylori and duodenal ulcer

目的探讨雷贝拉唑治疗小儿幽门螺杆菌十二指肠溃疡的临床疗效及安全性。方法回顾性分析62例幽门螺杆菌十二指肠溃疡患儿的临床资料，随机双盲法分为实验组和对照组，对照组采用奥美拉唑＋阿莫西林＋甲硝锉三联疗法治疗，实验组采用雷贝拉唑三联方案。比较两组临床疗效、溃疡愈合及复发情况。结果两组症状缓解时间对比差异未见统计学意义（P〉0．05），但溃疡愈合时间和幽门螺杆菌根除率指标方面实验组明显优于对照组（P〈0．05）。实验组治疗总有效率96．9％，显著高于对照组的86．7％，两组治愈率和总有效率对比差异具有统计学意义（P〈0．05）。实验组不良反应发生率12．5％，1年期复发率6．3％，均显著低于对照组的26．7％和16．7％，差异均具有统计学意义（P〈0．05）。结论采用以雷贝拉唑主导的三联疗法治疗小儿幽门螺杆菌十二指肠溃疡疗效确切，能有效促进溃疡愈合，减少复发，安全可靠，值得临床广泛推广应用。

Objective To investigate the clinical efficacy and safety of rabeprazole in treatment of children with H. pylori and duodenal ulcer. Methods Clinical data of 62 children with H. pylori and duodenal ulcer was retrospectively analyzed, and they were randomly divided into experiment group and control group. The control group with Ogilvy omeprazole ＋ amoxicillin ＋ metronidazole file triple therapy, experiment group with rabeprazole triple regimen. The clinical efficacy, ulcer healing and recurrence of the two groups were compared. Results The remission time of the two groups had no significant difference （P 〉 0. 05 ）, but the healing time of ulcers and H. pylori eradication rate targets in the experiment group were better than those in the control group （P 〈 0. 05 ）. The total efficiency of the experiment treatment group was 96. 9%, which was higher than that in the control group（86. 7% ）, and there was significant difference （P 〈0. 05）. The in- cidence of adverse reactions in the experiment group（ 12. 5% ） and 1 year recurrence rate（6. 3% ） were significantly lower than those of the control group （26. 7%, 16. 7% ）, the differences were significant （P 〈 0. 05 ）. Conclusions Adopt a leading rabeprazole triple therapy is effective in children with Helicobacter pylori and duodenal ulcers, which can effectively promote ulcer healing and reduce recurrence, it is safe, reliable, worthy of wider application.